Share on StockTwits

Cytomedix (NASDAQ:CMXI) CEO Martin P. Rosendale acquired 25,000 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, August 20th. The stock was purchased at an average price of $0.40 per share, for a total transaction of $10,000.00. Following the completion of the transaction, the chief executive officer now directly owns 229,149 shares in the company, valued at approximately $91,660. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Cytomedix (NASDAQ:CMXI) traded down 3.50% on Friday, hitting $0.386. The stock had a trading volume of 126,400 shares. Cytomedix has a 1-year low of $0.33 and a 1-year high of $0.68. The stock’s 50-day moving average is $0.39 and its 200-day moving average is $0.47. The company’s market cap is $48.0 million.

Cytomedix, Inc is a United States-based company that develops biologically active regenerative therapies for wound and tissue repair.

Receive News & Ratings for Cytomedix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytomedix Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.